What question did this study set out to answer?

To evaluate the impact of TP53 alterations on overall survival in patients with mantle cell lymphoma.

December 8, 2025BloodOpen Access

Biallelic TP53 alterations predict poorer survival in Mantle Cell Lymphoma: Insights from a national real-world cohort high-touch project

View Full Paper

Ask AI

Bookmark

Authors

Real-world data shows TP53 mutations reduce overall survival in mantle cell lymphoma, suggesting urgent need for new therapies.

To evaluate the impact of TP53 alterations on overall survival in patients with mantle cell lymphoma.
Utilized Flatiron Health Research Database for patient data.
Included patients diagnosed with MCL between January 2014 and April 2024.
Evaluated overall survival using Kaplan-Meier curves and log-rank tests.
Median overall survival was 74.3 months for the cohort.
rwOS was lowest in patients with both del17p and TP53 mutation at 23 months.
Statistically significant differences in rwOS were found amongst different genetic subtypes.

Bliven et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark